Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeted RNA-seq of BCP-ALL pediatric patients

ABSTRACT: Targeted RNA-seq of BCP-ALL pediatric patients

PROVIDER: PRJEB42250 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR5023250_1.fastq.gz	Fastqsanger.gz
	ERR5023250_2.fastq.gz	Fastqsanger.gz
	ERR5023260_1.fastq.gz	Fastqsanger.gz
	ERR5023260_2.fastq.gz	Fastqsanger.gz
	ERR5023270_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 232

Similar Datasets

Targeted RNA-seq of BCP-ALL pediatric patients

Project description:Targeted RNA-seq of pediatric infant (<1year of age at diagnosis) patients affected by B-cell precursor Acute Lymphoblastic leukemia (BCP-ALL). The aim of the study is to identify fusion gene rearrangements involved in childhood leukemia, using a custom targeted panel for RNA analysis by NGS.

2021-10-25 | E-MTAB-9971 | biostudies-arrayexpress

Whole transcriptome analysis to detect fusion genes in pediatric BCP-ALL

Project description:Whole transcriptome RNA-seq of pediatric infant (<1year of aget at diagnosis) patients affected by B-cell precursor Acute Lymphoblastic leukemia (BCP-ALL). The aim of the study is to identify fusion gene rearrangements involved in childhood leukemia, using Next Generation Sequencing (NGS)

2021-10-25 | E-MTAB-9925 | biostudies-arrayexpress

Expression data from mesenchymal stromal cells derived from pediatric leukemia patients and healthy pediatric controls

Project description:B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells reside in the bone marrow microenvironment, where they are protected against chemotherapeutic agents. Mesenchymal stromal cells (MSCs) are key components of this supporting framework. The present study aimed to unravel whether MSCs derived from pediatric BCP-ALL patients (leukemic MSCs) differ from MSCs derived from healthy pediatric donors (control-MSCs). Therefore, we studied their gene expression profiles.

2020-07-13 | GSE101425 | GEO

B-other pediatric BCP-ALL analysis by Target Capture NGS panel

Project description:We applied a targeted NGS analysis in order to identify fusion genes in pediatric patients affected by B-cell precursor ALL and enrolled in the AIEOP-BFM treatment protocol in Italian centers 2017

2022-09-30 | E-MTAB-11319 | biostudies-arrayexpress

Down syndrome pediatric BCP-ALL analysis by Target Capture NGS panel

Project description:We applied a targeted NGS analysis in order to identify fusion genes in pediatric patients with Down Syndrome and affected by B-cell precursor ALL and enrolled in the AIEOP-BFM treatment protocol in Italian centers

2023-04-12 | E-MTAB-11686 | biostudies-arrayexpress

Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia

Project description:In contrast to patients with B cell precursor acute lymphoblastic leukemia (BCP-ALL), patients with acute myeloid leukemia (AML) have not yet benefited from recent advances in targeted immunotherapy. Repurposing immunotherapies that have been successfully used to target other hematological malignancies could, in case of a shared target antigen, represent a promising opportunity to expand the immunotherapeutic options for AML. Here, we evaluated the expression of CD19 in a large pediatric AML cohort, assessed the ex vivo AML killing efficacy of CD19-directed immunotherapies, and characterized the bone marrow immune microenvironment in pediatric AML, BCP-ALL, and non-leukemic controls. Out of 167 newly diagnosed de novo pediatric AML patients, 18 patients (11%) had CD19+ AML, with 61% carrying the translocation t(8;21)(q22;q22). Among CD19+ samples, we observed a continuum of CD19 expression levels on AML cells. In individuals exhibiting unimodal and high CD19 expression, the antigen was consistently present on nearly all CD34+CD38- and CD34+CD38+ subpopulations. In ex vivo AML-T cell co-cultures, blinatumomab demonstrated substantial AML killing, with an efficacy similar to BCP-ALL. In addition, CAR T cells could effectively eliminate CD19+ AML cells ex vivo. Furthermore, our immunogenomic assessment of the bone marrow immune microenvironment of newly diagnosed pediatric t(8;21) AML revealed that T- and NK cells had a less exhausted and senescent phenotype in comparison to pediatric BCP-ALL. Altogether, our study underscores the promise of CD19-directed immunotherapies for the treatment of pediatric CD19+ AML.

2024-08-08 | GSE270185 | GEO

Down syndrome pediatric BCP-ALL analysis by Target Capture NGS panel

Project description:Down syndrome pediatric BCP-ALL analysis by Target Capture NGS panel

| PRJEB52620 | ENA

B-other pediatric BCP-ALL analysis by Target Capture NGS panel

Project description:B-other pediatric BCP-ALL analysis by Target Capture NGS panel

| PRJEB50050 | ENA

Whole transcriptome analysis to detect fusion genes in pediatric BCP-ALL

Project description:Whole transcriptome analysis to detect fusion genes in pediatric BCP-ALL

| PRJEB42067 | ENA

Lnc-RNA expression pattern in ETV6/RUNX1-driven b-cell precursor acute lymphoblastic leukemia (BCP-ALL)

Project description:Overwhelming evidence indicates that long non-coding RNAs have essential roles in tumorigenesis. Nevertheless, their expression and role in pediatric B-cell precursor acute lymphoblastic leukemia has not been extensively explored. Here, we conducted a comprehensive analysis of the long non-coding RNA transcriptome in ETV6/RUNX1 positive BCP-ALL, one of the most frequent subtypes of pediatric leukemia. An ETV6/RUNX1 expression signature was established, consisting of 596 lncRNAs (434 up and 162 down) using expression analysis of a series of primary patient samples. Subsequently, RNA sequencing from BCP-ALL cell lines and shRNA-mediated silencing of ETV6/RUNX1, illustrated that lnc-NKX2-3-1, lnc-TIMM21-5, lnc-ASTN1-1 and lnc-RTN4R-1 are bona fide ETV6/RUNX1 targets and could serve as novel biomarkers of this prevalent subtype of human leukemia.

2016-09-26 | GSE79869 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data